Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Dallas, Texas 75247


This is a randomized, single-center, open-label, 2-sequence, 2-period, single-dose, crossover study to assess the bioequivalence and the total 24-hour urinary glucose excretion (UGE) of 400 mg LX4211 administered as a single 400-mg tablet compared to 2 × 200-mg tablets in healthy subjects under fasted conditions.


Inclusion Criteria: - Adult subjects ≥18 to ≤55 years of age - Willing and able to provide written informed consent Exclusion Criteria: - Presence of clinically significant physical, laboratory, or ECG findings that, in the opinion of the Investigator and/or Sponsor, may interfere with any aspect of study conduct or interpretation of results - Existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of LX4211 - History of renal disease, or significantly abnormal kidney function test at Screening - History of hepatic disease, or significantly abnormal liver function tests at Screening - History of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine, cardiovascular, neurological, hematological, or GI abnormality



Primary Contact:

Study Director
Suman Wason, M.D.
Lexicon Pharmaceuticals, Inc.

Backup Contact:


Location Contact:

Dallas, Texas 75247
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.